Bowel cancer drug resistance clues uncovered

16 June 2025

Scientists at The Institute of Cancer Research, London, claim to have discovered what may cause some treatments to stop working in people living with bowel cancer.

The findings could help researchers use information about a person’s cancer to make better use of current treatments and develop more targeted therapies for bowel cancer, designed to stay one step ahead of the disease.

In research published in Cancer Research, the team studied bowel cancer organoids, tiny lab-grown versions of human organs that model how cancer cells behave in our bodies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company Spotlight